If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Busy Schedule: Amid Setbacks, AstraZeneca Has Been Revamping And Making Deals

by Lisa M. Jarvis
July 30, 2012 | A version of this story appeared in Volume 90, Issue 31

Dec. 20, 2011 Development of the ovarian cancer drug olaparib is dropped, and the depression drug TC-5214 fails. AstraZeneca takes a $382 million charge.

Jan. 19, 2012 FDA asks AstraZeneca and partner Bristol-Myers Squibb for more data on diabetes drug dapagliflozin.

Feb. 2 Restructuring is unveiled. Some 7,300 jobs—2,100 in R&D—are planned to be cut, and R&D facilities in Canada and Sweden are slated to close.

March 27 Generic versions of AstraZeneca’s multi-billion-dollar psychosis drug Seroquel are launched.

April 2 AstraZeneca pays $50 million to Amgen for the rights to codevelop five Amgen antibodies.

April 23 AstraZeneca acquires Ardea Biosciences for $1.26 billion. The deal brings clinical-stage compounds for gout and cancer.

April 26 AstraZeneca CEO David Brennan steps down; Simon Lowth is named interim CEO.

May 3 AstraZeneca and other companies team with the National Institutes of Health and academic investigators to find new uses for old drug candidates.

May 24 AstraZeneca joins a consortium for new antibiotics. Drug companies commit $140 million to the effort.

June 30 BMS agrees to buy Amylin for $7 billion. AstraZeneca says it will pay $3.4 billion for an equal stake in the diabetes drug firm.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.